Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 14-arm NCT04198766

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors

Sponsor: Inhibrx Biosciences, Inc

Conditions Gastric Cancer Head and Neck Cancer Melanoma Non-Small Cell Lung Cancer Renal Cell Carcinoma Solid Tumor Urothelial Carcinoma

Interventions Carboplatin AUC-5 Carboplatin AUC-6 Cisplatin 75mg/m2 INBRX-106 - Hexavalent OX40 agonist antibody Nab paclitaxel 100mg/m2 Paclitaxel 200mg/m2 Pemetrexed 500 mg/m2 pembrolizumab 200 mg pembrolizumab 400 mg

Updated 25 times since 2020 Last updated: Dec 17, 2025 Started: Dec 10, 2019 Primary completion: Oct 30, 2026 Completion: May 12, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04198766, this PHASE1/PHASE2 trial focuses on Gastric Cancer and Head and Neck Cancer and remains ongoing. Sponsored by Inhibrx Biosciences, Inc, it has been updated 25 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

25 versions recorded

Jan 2026 — Present [monthly]

Active Not Recruiting PHASE1/PHASE2

Status: Recruiting → Active Not Recruiting
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE1/PHASE2
Oct 2025 — Dec 2025 [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Oct 2025 [monthly]

Recruiting PHASE1/PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1 → PHASE1/PHASE2

▶ Show 20 earlier versions

Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1
Mar 2024 — Jul 2024 [monthly]

Recruiting PHASE1
Nov 2023 — Mar 2024 [monthly]

Recruiting PHASE1
Sep 2023 — Nov 2023 [monthly]

Recruiting PHASE1
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE1
Apr 2023 — Aug 2023 [monthly]

Recruiting PHASE1
Feb 2023 — Apr 2023 [monthly]

Recruiting PHASE1
Jun 2022 — Feb 2023 [monthly]

Recruiting PHASE1
Mar 2022 — Jun 2022 [monthly]

Recruiting PHASE1
Jan 2022 — Mar 2022 [monthly]

Recruiting PHASE1
Sep 2021 — Jan 2022 [monthly]

Recruiting PHASE1
Feb 2021 — Sep 2021 [monthly]

Recruiting PHASE1
Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE1
Nov 2020 — Jan 2021 [monthly]

Recruiting PHASE1
Oct 2020 — Nov 2020 [monthly]

Recruiting PHASE1
Jul 2020 — Oct 2020 [monthly]

Recruiting PHASE1
May 2020 — Jul 2020 [monthly]

Recruiting PHASE1
Apr 2020 — May 2020 [monthly]

Recruiting PHASE1
Feb 2020 — Apr 2020 [monthly]

Recruiting PHASE1
Jan 2020 — Feb 2020 [monthly]

Recruiting PHASE1

First recorded

Dec 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Inhibrx Biosciences, Inc
Merck Sharp & Dohme LLC

Data source: Inhibrx Biosciences, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Billings, United States , Changhua, Taiwan , Chicago, United States , Clermont, United States , Cleveland, United States , Dallas, United States , Detroit, United States , Duarte, United States , El Paso, United States and 25 more locations